Literature DB >> 21264841

The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients.

Terri S Armstrong1, Elizabeth Vera-Bolanos, Ibrahima Gning, Alvina Acquaye, Mark R Gilbert, Charles Cleeland, Tito Mendoza.   

Abstract

BACKGROUND: Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor (PBT) patients. Development of disease-related symptoms is predictive of tumor recurrence in other cancers but has not been reported in the PBT population.
METHODS: A cross-sectional sample of 294 PBT patients participated. Progression was based on the radiologist report of the magnetic resonance imaging (MRI). The relation of clinical variables (age, extent of resection, tumor grade, and Karnofsky performance status [KPS]) and MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) mean symptom and interference subscales with progression was examined using logistic regression.
RESULTS: The study enrolled more men (60%, n = 175); median age was 46 years. The majority had less than a gross total resection (n = 186, 64%), and a good KPS (KPS ≥ 90) (N = 208). The majority had a grade 3 or 4 tumor (n = 199) and 24% of patients had recurrence. Tumor grade and activity-related interference were significantly related to progression. Patients with tumor grade 4 were 2.4 times more likely to have recurrence (95% CI, 1.2-5.; P < .015). Patients with significant (ratings of ≥ 5) activity-related interference were 3.8 times more likely to have recurrence (95% CI, 2.14-6.80; P < .001). Mean activity-related score was 4.8 for those with progression on MRI and 2.2 for those with stable disease.
CONCLUSIONS: Significant activity-related interference and tumor grade were associated with recurrence but not KPS, age, or extent of resection. These results provide preliminary support for the use of symptom interference in assessment of disease status. Because the authors used a cross-sectional sample, future studies evaluating change over time are needed.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21264841     DOI: 10.1002/cncr.25892

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  See brain cancer as more than just the sum of biology.

Authors:  Terri Armstrong
Journal:  Nature       Date:  2018-09       Impact factor: 49.962

2.  Impact of recall period on primary brain tumor patient's self-report of symptoms.

Authors:  Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina Acquaye; Mark R Gilbert; Tito R Mendoza
Journal:  Neurooncol Pract       Date:  2014-05-05

3.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 4.  Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Authors:  Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 5.  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Authors:  Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

6.  Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.

Authors:  Shota Tanaka; Iori Sato; Masamichi Takahashi; Terri S Armstrong; Charles S Cleeland; Tito R Mendoza; Akitake Mukasa; Shunsaku Takayanagi; Yoshitaka Narita; Kiyoko Kamibeppu; Nobuhito Saito
Journal:  Jpn J Clin Oncol       Date:  2020-07-09       Impact factor: 3.019

7.  The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms.

Authors:  Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina A Acquaye; Mark R Gilbert; Harshad Ladha; Tito Mendoza
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

8.  Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT).

Authors:  Lin Lin; Alvina A Acquaye; Elizabeth Vera-Bolanos; Jennifer E Cahill; Mark R Gilbert; Terri S Armstrong
Journal:  J Neurooncol       Date:  2012-09-11       Impact factor: 4.130

9.  Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer.

Authors:  Bradley J Barney; Xin Shelley Wang; Charles Lu; Zhongxing Liao; Valen E Johnson; Charles S Cleeland; Tito R Mendoza
Journal:  Qual Life Res       Date:  2013-01-31       Impact factor: 4.147

Review 10.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.